The Trump administration's proposal to add political oversight to federal research grants is facing fierce opposition from scientists, biotech leaders, and patient advocates. The Office of Management and Budget plan would make political appointees review grant requests and reduce peer review to an advisory role. Critics warn it could cripple U.S. biomedical research leadership at a time when China is rapidly gaining ground.
The Trump administration's Office of Management and Budget (OMB) has proposed a sweeping overhaul of the federal grant-making process — and the backlash has been swift and loud. The plan would require political appointees to conduct pre-issuance reviews of discretionary grants, demoting scientific peer review to merely advisory status. It would also give agencies broader authority to terminate grants that no longer align with "administration priorities" or the "national interest."
The proposal has drawn over 93,000 public comments — an unusually high volume — with overwhelming opposition from academic scientists, biotech executives, patient advocacy groups, and even some Republican lawmakers. Industry groups like PhRMA and BIO warn the move could drive talent, investment, and discoveries overseas, while critics inside and outside government say it would destabilize NIH and other health agencies already reeling from staff departures and grant terminations.
By the Numbers:
Why it matters: The U.S. has long led the world in biomedical innovation, but that edge depends on a research funding system driven by scientific merit. Injecting political considerations into grant decisions risks slowing medical progress by months, years, or even decades — and could hand China a significant competitive advantage in the global race for scientific leadership.
